Nucleic Acid Polymers with Accelerated Plasma and Tissue Clearance for Chronic Hepatitis B Therapy

• Auteurs principaux: Ingo Roehl (Auteur), Stephan Seiffert (Auteur), Celia Brikh (Auteur), Jonathan Quinet (Auteur), Catherine Jamard (Auteur), Nadine Dorfler (Auteur), Jennifer A. Lockridge (Auteur), Lucyna Cova (Auteur), Andrew Vaillant (Auteur)
• Format: Livre
• Publié: Elsevier, 2017-09-01T00:00:00Z.
• Sujets: article
• Accès en ligne: Connect to this object online.

REP 2139 is a nucleic acid polymer (NAP) currently under clinical development for chronic hepatitis B (HBV) therapy. This preclinical study investigated different REP 2139 analogs that would display reduced accumulation in the serum and tissues, while retaining an antiviral effect against HBV infect...